Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB-1015 |
Synonyms | |
Therapy Description |
AB-1015 is an integrated circuit T (ICT) cell therapy that comprises T cells engineered to express a priming receptor that binds to ALPG/P and induces expression of a chimeric antigen receptor (CAR) that targets mesothelin (MSLN), as well as shRNA that targets FAS and PTPN2, potentially resulting in increased killing of ALPG/P and MSLN-expressing tumor cells (Cancer Res (2022) 82 (12_Supplement): 585). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB-1015 | AB 1015|AB1015 | AB-1015 is an integrated circuit T (ICT) cell therapy that comprises T cells engineered to express a priming receptor that binds to ALPG/P and induces expression of a chimeric antigen receptor (CAR) that targets mesothelin (MSLN), as well as shRNA that targets FAS and PTPN2, potentially resulting in increased killing of ALPG/P and MSLN-expressing tumor cells (Cancer Res (2022) 82 (12_Supplement): 585). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05617755 | Phase I | AB-1015 | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer | Active, not recruiting | USA | 0 |